Strategic Collaborations TESARO’s collaboration history and active Jemperli development create a ready path for licensing or co development deals with biotech partners seeking to expand immunotherapy combinations. Position as a partner to supply dostarlimab or co-develop new regimens, leveraging Alteogen for subcutaneous delivery where applicable, and offer alliance management and contract optimization services to reduce risk and accelerate deals.

Delivery Format Expansion The subcutaneous dostarlimab program with Alteogen signals demand for patient friendly delivery and scalable manufacturing. This opens doors for partnerships with device manufacturers or CMOs for fill finish, formulation development, and logistics, as well as health system training and patient support programs to drive uptake.

AI Enabled R&D TESARO’s tech stack suggests data driven R&D and operations. A business development approach could offer AI and analytics partnerships for trial design, biomarker discovery, predictive safety monitoring, and real world data integrations to demonstrate value, optimize study outcomes, and support faster market access.

Growth Financing Levers With substantial funding and mid range revenue, TESARO has financial capacity for milestone driven deals and co development arrangements. Propose flexible deal structures with upfronts, milestones, and royalties for licensing or collaboration agreements, plus scalable manufacturing partnerships to support growth.

IP Risk Management Recent collaboration related litigation highlights IP and contract risk in partnerships. Position your offerings as risk aware BD support, including due diligence, robust contract templates, clear IP scoping, and termination/change of terms clauses to de risk deals and build confidence with collaborators.